Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today presents its net-sales performance for the third quarter and first nine months of 2026.
- Q3 net sales up by 5% at CC1,2; biosimilar net sales up by 17% at CC, with generics net sales stable at CC. Excluding the anti-infective B2B headwind3, total net sales increased by 7% at CC and generics net sales increased by 2% at CC. This adverse impact is expected to be immaterial in Q4 2026 and next year
- 9M net sales up by 5% at CC; biosimilar net sales up by 19% at CC, with generics net sales declining by 1% at CC. Excluding the anti-infective B2B headwind, 9M net sales increased by 6% at CC, while generics net sales were stable at CC
- Biosimilars represented 34% of Q3 2026 net sales
- North America led in the quarter, with net-sales growth of 20% at CC, driven by biosimilars
- Capital Markets Day: Bio100 ambition unveiled, targeting more than 100 biosimilars in the portfolio by 2040
- Full-year guidance: net-sales growth at CC narrowed to 5-6% and an upgrade to core-EBITDA margin to 23.0-23.5%
Q3 USD millions | Q3 2026 | Q3 2025 | change % | change CC % |
|
|
|
|
|
Biosimilars | 998 | 862 | 16% | 17% |
Generics | 1,944 | 1,963 | -1% | 0% |
Net sales | 2,942 | 2,825 | 4% | 5% |
9M
| 9M 2026 | 9M 2025 | change % | change CC % |
|
|
|
|
|
Biosimilars | 2,873 | 2,358 | 22% | 19% |
Generics | 5,830 | 5,699 | 2% | -1% |
Net sales | 8,703 | 8,057 | 8% | 5% |
Richard Saynor, Chief Executive Officer of Sandoz, says: “Sandoz made further progress in the third quarter, reflecting the strength of a growing portfolio and continued momentum in biosimilars. We also continued to strengthen the foundations for our long-term growth by expanding our biosimilar pipeline to 40 assets and achieving more milestones with our biosimilar hub in Slovenia.
“At our recent Capital Markets Day, we unveiled our Bio100 ambition and set out a clear roadmap to maximise the significant opportunity in biosimilars. We aim to build a portfolio of more than 100 biosimilars by 2040, supported by our differentiated development and manufacturing network, an unprecedented wave of upcoming loss-of-exclusivity opportunities, and an increasingly supportive regulatory environment. With these advantages, we are well positioned to create sustainable shareholder value and expand access for patients around the world.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.